<DOC>
	<DOCNO>NCT01829295</DOCNO>
	<brief_summary>In First-line Antimetabolites Steroid-sparing Treatment ( FAST ) Uveitis Trial , investigator propose establish immunosuppressive therapy , methotrexate mycophenolate mofetil , effective first-line , corticosteroid-sparing agent treatment non-infectious uveitis block-randomized , observer-masked , comparative effectiveness trial .</brief_summary>
	<brief_title>Methotrexate Mycophenolate Mofetil UVEITIS</brief_title>
	<detailed_description>This randomized comparative effectiveness trial determine treatment , methotrexate mycophenolate mofetil , effective first-line corticosteroid-sparing treatment patient non-infectious intermediate , posterior panuveitis require corticosteroid-sparing therapy . The primary outcome treatment success assess 6 month visit ( Phase 1 , 0-6 month ) . If patient treatment success , continue medication another 6 month ( Phase 1 , 6-12 month ) . Patients treatment failure crossover medication ( Phase 2 , 0-6 month ) .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antimetabolites</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>All following criterion must meet enrollment : Historical noninfectious intermediate , anterior intermediate , posterior panuveitis least one eye Active inflammation within last 180 day , define presence follow ( least one eye ) accord SUN criterion : ≥ 2+ anterior chamber cell ≥ 2+ vitreous haze active retinal choroidal lesion Active inflammation enrollment , define presence follow ( least one eye ) accord SUN criterion : ≥1+ anterior chamber cell and/or ≥1+ vitreous haze and/or active retinal/choroidal lesion At least one follow criterion must meet enrollment : Active inflammation 4 week highdose ( 1mg/kg prednisone equivalent ) corticosteroid treatment 4 week follow regional corticosteroid injection Treatment oral corticosteroid result reduction inflammation , follow increase inflammation ( least 1 grade anterior chamber cell vitreous haze change nonactive active lesion ) corticosteroid taper , 180 week prior enrollment Active inflammation longacting corticosteroid injection 4 week 180 day prior enrollment Active inflammation treatment &gt; 10mg/day oral prednisone least past 90 day prior enrollment Known chronic condition necessitate corticosteroidsparing immunosuppressive treatment : Behcet 's disease posterior segment involvement , multifocal choroiditis panuveitis , serpiginous choroidopathy , birdshot retinochoroidopathy , diffuse retinal vasculitis , VogtKoyanagiHarada bullous serous retinal detachment and/or choroidal detachment , sympathetic ophthalmia . No prior therapy require patient Willingness start corticosteroid treatment 1mg/kg 60mg day prednisone , whichever less Willingness limit alcohol consumption Willingness use acceptable method contraception study period ( i.e . pharmacologics , device , barrier method ) abstinence . Any following Any infectious cause uveitis Prior immunosuppressive therapy corticosteroid past 12 month Prior intolerability safety issue methotrexate mycophenolate mofetil Prior failure control ocular inflammation use methotrexate mycophenolate mofetil Prior biologic therapy time Media opacity ( cataract and/or corneal scar ) and/or extensive posterior synechiae examination posterior segment possible eye Chronic hypotony ( IOP &lt; 5 mm Hg &gt; 3 month ) eye Periocular intravitreal corticosteroid injection past 4 week Fluocinolone acetonide implant either eye &lt; 3 year Intraocular surgery &lt; 30 day , plan get surgery within next 6 month Best spectaclecorrected visual acuity ( BSCVA ) hand motion worse good eye &lt; 16 year age enrollment Planning conceive study period , pregnant breastfeeding ( blood urine pregnancy test female , exclude postmenopausal mandatory ) * Any history cancer ( If patient history nonmelanoma skin cancer still consider inclusion study , provide currently active ) . Systemic autoimmune disease anticipated dictate treatment course Abnormal Complete blood count ( ≤ 2,500 white blood cell and/or ≤ 75,000 platelet and/or ≤9 hemoglobin ) within 4 week prior enrollment* Abnormal alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) ≥ 2 time upper limit normal lab and/or creatinine ≥ 1.5 within 4 week prior enrollment* Evidence active tuberculosis , HIV infection , syphilis , hepatitis B C ( patient must tuberculin skin test , interferongamma release assay , chest radiograph , RPR/VDRL , FTAABS , treponemal test , Hepatitis B surface antigen , Hepatitis C antibody test , HIV test within 90 day prior enrollment ) ** *Testing require within 4 week prior enrollment ; **Testing require within 90 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>antimetabolite , noninfectious</keyword>
</DOC>